Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Adenocarcinoma of the Gastroesophageal Junction”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01364493
What this trial is testing

Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer

Who this might be right for
Gastric Cancer
Peking University 51
Early research (Phase 1)Active Not RecruitingNCT04535401
What this trial is testing

Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines

Who this might be right for
Advanced Colorectal CarcinomaAdvanced Digestive System CarcinomaAdvanced Gastric Carcinoma+11 more
National Cancer Institute (NCI) 10
Large-scale testing (Phase 3)Not Yet RecruitingNCT07700979
What this trial is testing

Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma

Who this might be right for
Gastric / Gastroesophageal Junction Adenocarcinoma
Akeso 900
Testing effectiveness (Phase 2)Looking for participantsNCT06932068
What this trial is testing

Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma

Who this might be right for
HER2 NegativeLow PD-L1 ExpressingUnresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Qilu Hospital of Shandong University 77
Not applicableNot Yet RecruitingNCT07191405
What this trial is testing

Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors

Who this might be right for
ImmunotherapyChemotherapy
Second Affiliated Hospital, Zhejiang University, School of Medicine 156
Testing effectiveness (Phase 2)Study completedNCT02335411
What this trial is testing

Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Merck Sharp & Dohme LLC 318
Large-scale testing (Phase 3)Study completedNCT03042611
What this trial is testing

Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer

Who this might be right for
Gastric CancerGastric Adenocarcinoma
Elevar Therapeutics 460
Early research (Phase 1)Looking for participantsNCT06657144
What this trial is testing

CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

Who this might be right for
Metastatic Solid TumorAdvanced Solid Tumor
Coherus Oncology, Inc. 154
Large-scale testing (Phase 3)Looking for participantsNCT07221149
What this trial is testing

Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

Who this might be right for
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Bristol-Myers Squibb 690
Testing effectiveness (Phase 2)Study completedNCT00711243
What this trial is testing

Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor

Who this might be right for
Gastric CancerUnspecified Adult Solid Tumor, Protocol Specific
Northwestern University 59
Testing effectiveness (Phase 2)Study completedNCT01956149
What this trial is testing

Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Gastric Cancer

Who this might be right for
Gastric Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 65
Not applicableActive Not RecruitingNCT06243757
What this trial is testing

Minimally Invasive Proximal Gastrectomy Versus Minimally Invasive Total Gastrectomy for Gastric and Gastroesophageal Junction Cancers

Who this might be right for
Gastric CancerGastroEsophageal CancerGastroesophageal Junction Adenocarcinoma
Memorial Sloan Kettering Cancer Center 4
Testing effectiveness (Phase 2)Active Not RecruitingNCT03641313
What this trial is testing

Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

Who this might be right for
Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+5 more
National Cancer Institute (NCI) 17
Large-scale testing (Phase 3)Looking for participantsNCT07431281
What this trial is testing

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Who this might be right for
Gastric CancerGastroesophageal Junction AdenocarcinomaEsophageal Cancer
AstraZeneca 2,130
Testing effectiveness (Phase 2)Study completedNCT04014075
What this trial is testing

DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)

Who this might be right for
Adenocarcinoma Gastric Stage IV With MetastasesAdenocarcinoma - GEJ
Daiichi Sankyo 79
Large-scale testing (Phase 3)Study completedNCT03777657
What this trial is testing

Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

Who this might be right for
Gastric, or Gastroesophageal Junction Adenocarcinoma
BeiGene 997
Large-scale testing (Phase 3)Looking for participantsNCT07392892
What this trial is testing

Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

Who this might be right for
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal AdenocarcinomaMetastatic Gastric CancerGastroesophageal Junction Cancer+1 more
Pfizer 840
Testing effectiveness (Phase 2)Study completedNCT00074009
What this trial is testing

Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric Cancer
Memorial Sloan Kettering Cancer Center
Large-scale testing (Phase 3)Study completedNCT05008783
What this trial is testing

AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Akeso 610
Testing effectiveness (Phase 2)Study completedNCT00607594
What this trial is testing

Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer

Who this might be right for
Adenocarcinoma of the Gastroesophageal JunctionAdenocarcinoma of the StomachRecurrent Gastric Cancer+4 more
National Cancer Institute (NCI) 21
Next Page